{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:46:28Z","timestamp":1785890788777,"version":"3.56.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03207-0","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:54:48Z","timestamp":1780041288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies"],"prefix":"10.1186","volume":"23","author":[{"given":"Omid","family":"Salahi Ardekani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahya","family":"Zarezade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behshid","family":"Meymandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjes","family":"Azami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toran","family":"Shahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"3","key":"3207_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834]","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer. J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834].","journal-title":"J Clin"},{"issue":"7","key":"3207_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278]","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho AM, Laversanne M, Ferlay J, Colombet M, Pi\u00f1eros M, Znaor A, et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156(7):1336\u201346. https:\/\/doi.org\/10.1002\/ijc.35278].","journal-title":"Int J Cancer"},{"key":"3207_CR3","doi-asserted-by":"publisher","unstructured":"Zhu X, Fan C, Xiong Z, Chen M, Li Z, Tao T et al. Development and application of oncolytic viruses as the nemesis of tumor cells. Frontiers in Microbiology. 2023;Volume 14\u20132023. https:\/\/doi.org\/10.3389\/fmicb.2023.1188526..","DOI":"10.3389\/fmicb.2023.1188526."},{"key":"3207_CR4","doi-asserted-by":"publisher","unstructured":"Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discover Oncology. 2025;16(1):607. https:\/\/doi.org\/10.1007\/s12672-025-02198-8..","DOI":"10.1007\/s12672-025-02198-8."},{"key":"3207_CR5","doi-asserted-by":"publisher","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends in Cancer. 2023;9(2):122\u201339. https:\/\/doi.org\/10.1016\/j.trecan.2022.10.003.","DOI":"10.1016\/j.trecan.2022.10.003"},{"issue":"4","key":"3207_CR6","doi-asserted-by":"publisher","first-page":"e28729","DOI":"10.1002\/jmv.28729]","volume":"95","author":"Z Huang","year":"2023","unstructured":"Huang Z, Guo H, Lin L, Li S, Yang Y, Han Y, et al. Application of oncolytic virus in tumor therapy. J Med Virol. 2023;95(4):e28729. https:\/\/doi.org\/10.1002\/jmv.28729].","journal-title":"J Med Virol"},{"key":"3207_CR7","doi-asserted-by":"publisher","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nature Reviews Clinical Oncology. 2023;20(3):160\u201377. https:\/\/doi.org\/10.1038\/s41571-022-00719-w.","DOI":"10.1038\/s41571-022-00719-w"},{"key":"3207_CR8","doi-asserted-by":"publisher","unstructured":"Donina S, Strele I, Proboka G, Auzin\u0161 J, Alberts P, Jonsson B et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Research. 2015;25(5):421-6. https:\/\/doi.org\/10.1097\/cmr.0000000000000180.","DOI":"10.1097\/cmr.0000000000000180"},{"key":"3207_CR9","doi-asserted-by":"publisher","unstructured":"Liang M. Oncorine, the World First Oncolytic Virus Medicine and its Update in China. Curr Cancer Drug Targets. 2018;18(2):171-6. https:\/\/doi.org\/10.2174\/1568009618666171129221503.","DOI":"10.2174\/1568009618666171129221503"},{"issue":"12","key":"3207_CR10","first-page":"1666","volume":"23","author":"ZJ Xia","year":"2004","unstructured":"Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng. 2004;23(12):1666\u201370.","journal-title":"Ai Zheng"},{"key":"3207_CR11","doi-asserted-by":"publisher","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology. 2015;33(25):2780-8. https:\/\/doi.org\/10.1200\/jco.2014.58.3377.","DOI":"10.1200\/jco.2014.58.3377"},{"key":"3207_CR12","doi-asserted-by":"publisher","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nature Medicine. 2022;28(8):1630-9. https:\/\/doi.org\/10.1038\/s41591-022-01897-x.","DOI":"10.1038\/s41591-022-01897-x"},{"issue":"6","key":"3207_CR13","doi-asserted-by":"publisher","first-page":"e70352","DOI":"10.1002\/jbt.70352]","volume":"39","author":"M Asiri","year":"2025","unstructured":"Asiri M, Abdul Kareem Al-Hetty HR, Al-Dhelaan RA, Shehata SSZ, Bishoyi AK, Vashishth R, et al. Oncolytic Virus as a New Treatment Technology in Cancer. J Biochem Mol Toxicol. 2025;39(6):e70352. https:\/\/doi.org\/10.1002\/jbt.70352].","journal-title":"J Biochem Mol Toxicol"},{"key":"3207_CR14","doi-asserted-by":"publisher","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduction and Targeted Therapy. 2022;7(1):117. https:\/\/doi.org\/10.1038\/s41392-022-00951-x.","DOI":"10.1038\/s41392-022-00951-x"},{"issue":"4","key":"3207_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","volume":"127","author":"G Dock","year":"1904","unstructured":"Dock G. The influence of complicating diseases upon leuk\u00e6mia. Am J Med Sci (1827\u20131924). 1904;127(4):563.","journal-title":"Am J Med Sci (1827\u20131924)"},{"key":"3207_CR16","doi-asserted-by":"publisher","unstructured":"Xiao D, Zhang H, Liu Y, Li Y, Li G, Ning Y. Oncolytic viruses: advanced strategies in cancer therapy. Signal Transduction and Targeted Therapy. 2026;11(1):45. https:\/\/doi.org\/10.1038\/s41392-025-02343-3.","DOI":"10.1038\/s41392-025-02343-3"},{"issue":"20","key":"3207_CR17","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3390\/cells14201620","volume":"14","author":"J Smestad","year":"2025","unstructured":"Smestad J, Rieth J, Laux D, Milhem M. The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. Cells. 2025;14(20):1620. https:\/\/doi.org\/10.3390\/cells14201620.","journal-title":"Cells"},{"issue":"5007","key":"3207_CR18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252(5007):854\u20136. https:\/\/doi.org\/10.1126\/science.1851332.","journal-title":"Science"},{"key":"3207_CR19","doi-asserted-by":"publisher","unstructured":"Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor. Clinical Cancer Research. 2006;12(22):6737-47. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0759.","DOI":"10.1158\/1078-0432.Ccr-06-0759"},{"key":"3207_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.omto.2021.10.012","volume":"23","author":"S Yajima","year":"2021","unstructured":"Yajima S, Sugawara K, Iwai M, Tanaka M, Seto Y, Todo T. Efficacy and safety of a third-generation oncolytic herpes virus G47\u2206 in models of human esophageal carcinoma. Mol Ther Oncolytics. 2021;23:402\u201311. https:\/\/doi.org\/10.1016\/j.omto.2021.10.012.","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"3207_CR21","doi-asserted-by":"publisher","first-page":"201100","DOI":"10.1016\/j.omton.2025.201100","volume":"33","author":"R Ghavimi","year":"2025","unstructured":"Ghavimi R, Rahimian L, Mohammadi M, Dutta O, Mohan H, Chouljenko V, et al. Viral warriors: Unlocking the immune system\u2019s potential with oncolytic viruses in cancer immunotherapy. Mol Therapy Oncol. 2025;33(4):201100. https:\/\/doi.org\/10.1016\/j.omton.2025.201100.","journal-title":"Mol Therapy Oncol"},{"issue":"2","key":"3207_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Mossman KL. Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies. Mol Ther. 2014;22(2):251\u20136. https:\/\/doi.org\/10.1038\/mt.2013.220.","journal-title":"Mol Ther"},{"key":"3207_CR23","doi-asserted-by":"publisher","first-page":"113822","DOI":"10.1016\/j.jconrel.2025.113822","volume":"383","author":"N Ma","year":"2025","unstructured":"Ma N, Gao J, Pang X, Wu K, Yang S, Wei H, et al. Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification. J Controlled Release. 2025;383:113822. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113822.","journal-title":"J Controlled Release"},{"issue":"6","key":"3207_CR24","doi-asserted-by":"publisher","first-page":"101599","DOI":"10.1016\/j.gendis.2025.101599","volume":"12","author":"X Zhou","year":"2025","unstructured":"Zhou X, Hu S, Wang X. Recent advances in oncolytic virus combined immunotherapy in tumor treatment. Genes Dis. 2025;12(6):101599. https:\/\/doi.org\/10.1016\/j.gendis.2025.101599.","journal-title":"Genes Dis"},{"issue":"1","key":"3207_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","volume":"11","author":"J Ma","year":"2020","unstructured":"Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D, et al. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 2020;11(1):48. https:\/\/doi.org\/10.1038\/s41419-020-2236-3.","journal-title":"Cell Death Dis"},{"key":"3207_CR26","doi-asserted-by":"publisher","unstructured":"Chen C, Cillis J, Deshpande S, Park AK, Valencia H, Kim SI Oncolytic Virotherapy in Solid Tumors: A Current Review: C., Chen et al. BioDrugs. 2025:1\u201320. https:\/\/doi.org\/10.1007\/s40259-025-00743-z.","DOI":"10.1007\/s40259-025-00743-z"},{"issue":"7","key":"3207_CR27","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1128\/JVI.75.7.3474-3479.2001","volume":"75","author":"S Balachandran","year":"2001","unstructured":"Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol. 2001;75(7):3474\u20139. https:\/\/doi.org\/10.1128\/JVI.75.7.3474-3479.2001.","journal-title":"J Virol"},{"issue":"12","key":"3207_CR28","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1158\/0008-5472.CAN-09-4676","volume":"70","author":"M Shmulevitz","year":"2010","unstructured":"Shmulevitz M, Pan L-Z, Garant K, Pan D, Lee PW. Oncogenic Ras promotes reovirus spread by suppressing IFN-\u03b2 production through negative regulation of RIG-I signaling. Cancer Res. 2010;70(12):4912\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4676.","journal-title":"Cancer Res"},{"issue":"12","key":"3207_CR29","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1128\/jvi.02393-10","volume":"85","author":"ZD Cary","year":"2011","unstructured":"Cary ZD, Willingham MC, Lyles DS. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol. 2011;85(12):5708\u201317. https:\/\/doi.org\/10.1128\/jvi.02393-10.","journal-title":"J Virol"},{"issue":"4","key":"3207_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/cgt.2016.8","volume":"23","author":"A Takasu","year":"2016","unstructured":"Takasu A, Masui A, Hamada M, Imai T, Iwai S, Yura Y. Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther. 2016;23(4):107\u201313. https:\/\/doi.org\/10.1038\/cgt.2016.8.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"3207_CR31","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","volume":"72","author":"I Diaconu","year":"2012","unstructured":"Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012;72(9):2327\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2975.","journal-title":"Cancer Res"},{"issue":"4","key":"3207_CR32","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/cancers13040588","volume":"13","author":"K-T Jin","year":"2021","unstructured":"Jin K-T, Du W-L, Liu Y-Y, Lan H-R, Si J-X, Mou X-Z. Oncolytic virotherapy in solid tumors: the challenges and achievements. Cancers. 2021;13(4):588. https:\/\/doi.org\/10.3390\/cancers13040588.","journal-title":"Cancers"},{"issue":"9","key":"3207_CR33","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","volume":"26","author":"JM Santos","year":"2018","unstructured":"Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, et al. Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy. Mol Ther. 2018;26(9):2243\u201354. https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.001.","journal-title":"Mol Ther"},{"issue":"3\u20134","key":"3207_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1089\/hum.2020.277","volume":"32","author":"I Milenova","year":"2021","unstructured":"Milenova I, Lopez Gonzalez M, Quixabeira DC, Santos JM, Cervera-Carrascon V, Dong W, et al. Oncolytic adenovirus ORCA-010 activates Proinflammatory myeloid cells and facilitates T cell recruitment and activation by PD-1 blockade in melanoma. Hum Gene Ther. 2021;32(3\u20134):178\u201391. https:\/\/doi.org\/10.1089\/hum.2020.277.","journal-title":"Hum Gene Ther"},{"issue":"10","key":"3207_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/v9100266","volume":"9","author":"V Kemp","year":"2017","unstructured":"Kemp V, Dautzenberg IJ, Limpens RW, Van den Wollenberg DJ, Hoeben RC. Oncolytic reovirus infection is facilitated by the autophagic machinery. Viruses. 2017;9(10):266. https:\/\/doi.org\/10.3390\/v9100266.","journal-title":"Viruses"},{"issue":"10","key":"3207_CR36","doi-asserted-by":"publisher","first-page":"e20230053","DOI":"10.1084\/jem.20230053","volume":"220","author":"K DePeaux","year":"2023","unstructured":"DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, et al. An oncolytic virus\u2013delivered tgf\u03b2 Inhibitor overcomes the immunosuppressive tumor microenvironment. J Exp Med. 2023;220(10):e20230053. https:\/\/doi.org\/10.1084\/jem.20230053.","journal-title":"J Exp Med"},{"issue":"1","key":"3207_CR37","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1038\/s41467-021-26352-2","volume":"12","author":"A Lain\u00e9","year":"2021","unstructured":"Lain\u00e9 A, Labiad O, Hernandez-Vargas H, This S, Sanlaville A, L\u00e9on S, et al. Regulatory T cells promote cancer immune-escape through integrin \u03b1v\u03b28-mediated TGF-\u03b2 activation. Nat Commun. 2021;12(1):6228. https:\/\/doi.org\/10.1038\/s41467-021-26352-2.","journal-title":"Nat Commun"},{"key":"3207_CR38","doi-asserted-by":"publisher","unstructured":"Minott JA, van Vloten JP, Yates JG, Santry LA, Matuszewska K, Pereira M et al. Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer. Mol Therapy-Oncolytics. 2023;31. https:\/\/doi.org\/10.1016\/j.omto.2023.100748.","DOI":"10.1016\/j.omto.2023.100748"},{"issue":"3","key":"3207_CR39","doi-asserted-by":"publisher","first-page":"e004335","DOI":"10.1136\/jitc-2021-004335","volume":"10","author":"JP Van Vloten","year":"2022","unstructured":"Van Vloten JP, Matuszewska K, Minow MA, Minott JA, Santry LA, Pereira M, et al. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J Immunother Cancer. 2022;10(3):e004335. https:\/\/doi.org\/10.1136\/jitc-2021-004335.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3207_CR40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12915-023-01792-y","volume":"21","author":"BM Johnson","year":"2023","unstructured":"Johnson BM, Johnson AM, Heim M, Buckley M, Mortimer B, Berry JL, et al. Biomechanical stimulation promotes blood vessel growth despite VEGFR-2 inhibition. BMC Biol. 2023;21(1):290. https:\/\/doi.org\/10.1186\/s12915-023-01792-y.","journal-title":"BMC Biol"},{"key":"3207_CR41","doi-asserted-by":"publisher","first-page":"1003204","DOI":"10.37349\/ei.2025.1003204","volume":"5","author":"AA Aljabali","year":"2025","unstructured":"Aljabali AA, Bashatwah R, Gammoh O. The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment. Explor Immunol. 2025;5:1003204. https:\/\/doi.org\/10.37349\/ei.2025.1003204.","journal-title":"Explor Immunol"},{"issue":"6","key":"3207_CR42","doi-asserted-by":"publisher","first-page":"e40742","DOI":"10.7759\/cureus.40742","volume":"15","author":"MA Zolaly","year":"2023","unstructured":"Zolaly MA, Mahallawi W, Khawaji ZY, Alahmadi MA. The clinical advances of oncolytic viruses in cancer immunotherapy. Cureus. 2023;15(6):e40742. https:\/\/doi.org\/10.7759\/cureus.40742.","journal-title":"Cureus"},{"key":"3207_CR43","doi-asserted-by":"publisher","unstructured":"Jiang Z, Yang N, Jin J, Zhang Z, Lu H, Xu L et al. Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors. Journal for ImmunoTherapy of Cancer. 2025;13(6):e011642. https:\/\/doi.org\/10.1136\/jitc-2025-011642.","DOI":"10.1136\/jitc-2025-011642"},{"key":"3207_CR44","doi-asserted-by":"publisher","unstructured":"Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ et al. Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients. Clinical Cancer Research. 2017;23(14):3566-74. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2900.","DOI":"10.1158\/1078-0432.Ccr-16-2900"},{"issue":"9","key":"3207_CR45","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/vaccines11091448","volume":"11","author":"S Onnockx","year":"2023","unstructured":"Onnockx S, Baldo A, Pauwels K. Oncolytic Viruses: An Inventory of Shedding Data from Clinical Trials and Elements for the Environmental Risk Assessment. Vaccines. 2023;11(9):1448. https:\/\/doi.org\/10.3390\/vaccines11091448.","journal-title":"Vaccines"},{"key":"3207_CR46","doi-asserted-by":"publisher","unstructured":"Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev. 2010;21(2\u20133):127\u201334. https:\/\/doi.org\/10.1016\/j.cytogfr.2010.02.014.","DOI":"10.1016\/j.cytogfr.2010.02.014"},{"issue":"8","key":"3207_CR47","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1099\/vir.0.043281-0","volume":"93","author":"B Yaacov","year":"2012","unstructured":"Yaacov B, Lazar I, Tayeb S, Frank S, Izhar U, Lotem M, et al. Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. J Gen Virol. 2012;93(8):1664\u201372. https:\/\/doi.org\/10.1099\/vir.0.043281-0","journal-title":"J Gen Virol"},{"key":"3207_CR48","doi-asserted-by":"publisher","unstructured":"Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, \u00c1lvarez R, Mato-Berciano A, Gimenez-Alejandre M et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Journal for ImmunoTherapy of Cancer. 2021;9(11):e003254. https:\/\/doi.org\/10.1136\/jitc-2021-003254.","DOI":"10.1136\/jitc-2021-003254"},{"key":"3207_CR49","doi-asserted-by":"publisher","unstructured":"Soko GF, Kosgei BK, Meena SS, Ng YJ, Liang H, Zhang B et al. Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses. Front Immunol. 2024;15:1535647. https:\/\/doi.org\/10.3389\/fimmu.2024.1535647.","DOI":"10.3389\/fimmu.2024.1535647"},{"key":"3207_CR50","doi-asserted-by":"publisher","unstructured":"Wang S, Li Y, Xu C, Dong J, Wei J. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy. Journal for ImmunoTherapy of Cancer. 2024;12(3):e008431. https:\/\/doi.org\/10.1136\/jitc-2023-008431.","DOI":"10.1136\/jitc-2023-008431"},{"issue":"13","key":"3207_CR51","doi-asserted-by":"publisher","first-page":"2104763","DOI":"10.1002\/smll.202104763","volume":"18","author":"FHN Howard","year":"2022","unstructured":"Howard FHN, Al-Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, et al. Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus. Small. 2022;18(13):2104763. https:\/\/doi.org\/10.1002\/smll.202104763.","journal-title":"Small"},{"key":"3207_CR52","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.omto.2019.10.005","volume":"15","author":"P Sette","year":"2019","unstructured":"Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, et al. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Mol Ther Oncolytics. 2019;15:214\u201322. https:\/\/doi.org\/10.1016\/j.omto.2019.10.005.","journal-title":"Mol Ther Oncolytics"},{"key":"3207_CR53","doi-asserted-by":"publisher","unstructured":"Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Bar\u00e7\u0131n E, Mart\u00ednez-Quintanilla J et al. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021;27(3):889\u2013902. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2400.","DOI":"10.1158\/1078-0432.Ccr-20-2400"},{"key":"3207_CR54","doi-asserted-by":"publisher","unstructured":"Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB et al. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. 2010;17(10):1200-5. https:\/\/doi.org\/10.1038\/gt.2010.66.","DOI":"10.1038\/gt.2010.66"},{"key":"3207_CR55","doi-asserted-by":"publisher","unstructured":"Li L, Liu S, Han D, Tang B, Ma J. Delivery and Biosafety of Oncolytic Virotherapy. Front Oncol. 2020;10:475. https:\/\/doi.org\/10.3389\/fonc.2020.00475.","DOI":"10.3389\/fonc.2020.00475"},{"key":"3207_CR56","doi-asserted-by":"publisher","unstructured":"Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E et al. Phase I\/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme. Molecular Therapy. 2006;13(1):221-8. https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.016.","DOI":"10.1016\/j.ymthe.2005.08.016"},{"key":"3207_CR57","doi-asserted-by":"publisher","first-page":"v496","DOI":"10.1093\/annonc\/mdz253.039","volume":"30","author":"A Samson","year":"2019","unstructured":"Samson A, West E, Turnbull S, Scott K, Tidswell E, Kingston J, et al. 1213P - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity. Ann Oncol. 2019;30:v496. https:\/\/doi.org\/10.1093\/annonc\/mdz253.039.","journal-title":"Ann Oncol"},{"key":"3207_CR58","doi-asserted-by":"publisher","unstructured":"Jirovec E, Quixabeira DCA, Clubb JHA, Pakola SA, Kudling T, Arias V et al. Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors. Journal of Experimental & Clinical Cancer Research. 2024;43(1):297. https:\/\/doi.org\/10.1186\/s13046-024-03219-0.","DOI":"10.1186\/s13046-024-03219-0"},{"issue":"10","key":"3207_CR59","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/cancers10100356","volume":"10","author":"IR Eissa","year":"2018","unstructured":"Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N, et al. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers. 2018;10(10):356. https:\/\/doi.org\/10.3390\/cancers10100356","journal-title":"Cancers"},{"issue":"14","key":"3207_CR60","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/ijms26146900","volume":"26","author":"Y Xia","year":"2025","unstructured":"Xia Y, Li D, Yang K, Ou X. Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy. Int J Mol Sci. 2025;26(14):6900. https:\/\/doi.org\/10.3390\/ijms26146900","journal-title":"Int J Mol Sci"},{"key":"3207_CR61","doi-asserted-by":"publisher","unstructured":"Kulu Y, Dorfman JD, Kuruppu D, Fuchs BC, Goodwin JM, Fujii T et al. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther. 2009;16(4):291-7. https:\/\/doi.org\/10.1038\/cgt.2008.83.","DOI":"10.1038\/cgt.2008.83"},{"key":"3207_CR62","doi-asserted-by":"publisher","unstructured":"Tang G, Wang D, Zhao X, Feng Z, Chen Q, Shen Y. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles. Int J Mol Sci. 2023;24(4). https:\/\/doi.org\/10.3390\/ijms24043681.","DOI":"10.3390\/ijms24043681"},{"key":"3207_CR63","doi-asserted-by":"publisher","unstructured":"Scanlan H, Coffman Z, Bettencourt J, Shipley T, Bramblett DE. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers. Frontiers in Oncology. 2022;Volume 12\u20132022. https:\/\/doi.org\/10.3389\/fonc.2022.940019.","DOI":"10.3389\/fonc.2022.940019"},{"key":"3207_CR64","doi-asserted-by":"publisher","unstructured":"Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR et al. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Mol Ther. 2019;27(11):1930-8. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.020.","DOI":"10.1016\/j.ymthe.2019.08.020"},{"key":"3207_CR65","doi-asserted-by":"publisher","unstructured":"Guan Y, Ino Y, Fukuhara H, Todo T. 282. Antitumor Efficacy of Intravenous Administration of Oncolytic Herpes Simplex Virus Expressing Interleukin 12. Molecular Therapy. 2006;13:S108. https:\/\/doi.org\/10.1016\/j.ymthe.2006.08.336.","DOI":"10.1016\/j.ymthe.2006.08.336"},{"key":"3207_CR66","doi-asserted-by":"publisher","unstructured":"Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J et al. Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer Immunology Research. 2018;6(10):1161-73. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0309.","DOI":"10.1158\/2326-6066.Cir-18-0309"},{"issue":"138","key":"3207_CR67","doi-asserted-by":"publisher","first-page":"ra13877","DOI":"10.1126\/scitranslmed.3003578","volume":"4","author":"RA Adair","year":"2012","unstructured":"Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, et al. Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. Sci Transl Med. 2012;4(138):ra13877\u201377. https:\/\/doi.org\/10.1126\/scitranslmed.3003578.","journal-title":"Sci Transl Med"},{"issue":"4","key":"3207_CR68","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","volume":"79","author":"D Mahalingam","year":"2017","unstructured":"Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, et al. A phase II study of REOLYSIN\u00ae (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2017;79(4):697\u2013703. https:\/\/doi.org\/10.1007\/s00280-017-3260-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3207_CR69","doi-asserted-by":"publisher","unstructured":"Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018;10(422). https:\/\/doi.org\/10.1126\/scitranslmed.aam7577.","DOI":"10.1126\/scitranslmed.aam7577"},{"issue":"5","key":"3207_CR70","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/cells15050393","volume":"15","author":"M Fayyad-Kazan","year":"2026","unstructured":"Fayyad-Kazan M, Al-Tameemi S, Ouhtit A. Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation. Cells. 2026;15(5):393. https:\/\/doi.org\/10.3390\/cells15050393","journal-title":"Cells"},{"key":"3207_CR71","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jconrel.2021.02.035","volume":"332","author":"A Mato-Berciano","year":"2021","unstructured":"Mato-Berciano A, Morgado S, Maliandi MV, Farrera-Sal M, Gimenez-Alejandre M, Ginest\u00e0 MM, et al. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. J Controlled Release. 2021;332:517\u201328. https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.035.","journal-title":"J Controlled Release"},{"issue":"12","key":"3207_CR72","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/pharmaceutics13122192","volume":"13","author":"A Reale","year":"2021","unstructured":"Reale A, Calistri A, Altomonte J. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy. Pharmaceutics. 2021;13(12):2192. https:\/\/doi.org\/10.3390\/pharmaceutics13122192","journal-title":"Pharmaceutics"},{"key":"3207_CR73","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Castro J, Alemany R, Cascall\u00f3 M, Mart\u00ednez-Quintanilla J, del Mar Arriero M, Lassaletta \u00c1 et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Therapy. 2010;17(7):476\u201383. https:\/\/doi.org\/10.1038\/cgt.2010.4.","DOI":"10.1038\/cgt.2010.4"},{"key":"3207_CR74","doi-asserted-by":"publisher","unstructured":"Draganov DD, Santidrian AF, Minev I, Nguyen D, Kilinc MO, Petrov I et al. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. Journal of Translational Medicine. 2019;17(1):100. https:\/\/doi.org\/10.1186\/s12967-019-1829-z.","DOI":"10.1186\/s12967-019-1829-z"},{"key":"3207_CR75","doi-asserted-by":"publisher","first-page":"111573","DOI":"10.1016\/j.biopha.2021.111573","volume":"139","author":"C Yang","year":"2021","unstructured":"Yang C, Hua N, Xie S, Wu Y, Zhu L, Wang S, et al. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies. Biomed Pharmacother. 2021;139:111573. https:\/\/doi.org\/10.1016\/j.biopha.2021.111573.","journal-title":"Biomed Pharmacother"},{"key":"3207_CR76","doi-asserted-by":"publisher","unstructured":"Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE et al. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2021;163(3):481-9. https:\/\/doi.org\/10.1016\/j.ygyno.2021.10.069.","DOI":"10.1016\/j.ygyno.2021.10.069"},{"key":"3207_CR77","doi-asserted-by":"publisher","unstructured":"Ochiai H, Campbell SA, Archer GE, Chewning TA, Dragunsky E, Ivanov A et al. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res. 2006;12(4):1349-54. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-1595.","DOI":"10.1158\/1078-0432.Ccr-05-1595"},{"key":"3207_CR78","doi-asserted-by":"publisher","unstructured":"Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2391-7. https:\/\/doi.org\/10.1016\/j.juro.2012.07.097.","DOI":"10.1016\/j.juro.2012.07.097"},{"key":"3207_CR79","doi-asserted-by":"publisher","unstructured":"Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R et al. Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British Journal of Cancer. 2012;106(3):496\u2013507. https:\/\/doi.org\/10.1038\/bjc.2011.577.","DOI":"10.1038\/bjc.2011.577"},{"key":"3207_CR80","doi-asserted-by":"publisher","unstructured":"Yan Z, Zhang Z, Chen Y, Xu J, Wang J, Wang Z. Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments. Cancer Cell International. 2024;24(1):242. https:\/\/doi.org\/10.1186\/s12935-024-03424-z.","DOI":"10.1186\/s12935-024-03424-z"},{"key":"3207_CR81","doi-asserted-by":"publisher","unstructured":"Fretwell EC, Houldsworth A. Oncolytic Virus Therapy in a New Era of Immunotherapy, Enhanced by Combination with Existing Anticancer Therapies: Turn up the Heat! J Cancer. 2025;16(6):1782-93. https:\/\/doi.org\/10.7150\/jca.102285.","DOI":"10.7150\/jca.102285"},{"key":"3207_CR82","doi-asserted-by":"publisher","unstructured":"Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol. 2021;14(5):101056. https:\/\/doi.org\/10.1016\/j.tranon.2021.101056.","DOI":"10.1016\/j.tranon.2021.101056"},{"key":"3207_CR83","doi-asserted-by":"publisher","unstructured":"Du W, Na J, Zhong L, Zhang P. Advances in preclinical and clinical studies of oncolytic virus combination therapy. Front Oncol. 2025;15:1545542. https:\/\/doi.org\/10.3389\/fonc.2025.1545542.","DOI":"10.3389\/fonc.2025.1545542"},{"key":"3207_CR84","doi-asserted-by":"publisher","unstructured":"Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19(2):289\u201398. https:\/\/doi.org\/10.1200\/jco.2001.19.2.289.","DOI":"10.1200\/jco.2001.19.2.289"},{"key":"3207_CR85","doi-asserted-by":"publisher","unstructured":"Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C et al. Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012;18(7):2080-9. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-2181.","DOI":"10.1158\/1078-0432.Ccr-11-2181"},{"key":"3207_CR86","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhu M, Chi H, Liu Y, Yu G. The combination therapy of oncolytic virotherapy. Front Pharmacol. 2024;15:1380313. https:\/\/doi.org\/10.3389\/fphar.2024.1380313.","DOI":"10.3389\/fphar.2024.1380313"},{"key":"3207_CR87","doi-asserted-by":"publisher","unstructured":"Saha D, Rabkin SD, Martuza RL. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer. 2020;8(1). https:\/\/doi.org\/10.1136\/jitc-2019-000345.","DOI":"10.1136\/jitc-2019-000345"},{"issue":"1","key":"3207_CR88","doi-asserted-by":"publisher","first-page":"e28108","DOI":"10.1002\/jmv.28108","volume":"95","author":"Y Shen","year":"2023","unstructured":"Shen Y, Song W, Lin D, Zhang X, Wang M, Li Y, et al. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. J Med Virol. 2023;95(1):e28108. https:\/\/doi.org\/10.1002\/jmv.28108.","journal-title":"J Med Virol"},{"issue":"12","key":"3207_CR89","first-page":"4908","volume":"6","author":"C Heise","year":"2000","unstructured":"Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res. 2000;6(12):4908\u201314.","journal-title":"Clin Cancer Res"},{"key":"3207_CR90","doi-asserted-by":"publisher","unstructured":"Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T et al. A Randomized Phase II Study of FOLFOX6\/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clin Colorectal Cancer. 2018;17(3):231-9.e7. https:\/\/doi.org\/10.1016\/j.clcc.2018.03.001.","DOI":"10.1016\/j.clcc.2018.03.001"},{"issue":"18","key":"3207_CR91","doi-asserted-by":"publisher","first-page":"10211","DOI":"10.3390\/ijms231810211","volume":"23","author":"F Busato","year":"2022","unstructured":"Busato F, Khouzai BE, Mognato M. Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art. Int J Mol Sci. 2022;23(18):10211. https:\/\/doi.org\/10.3390\/ijms231810211","journal-title":"Int J Mol Sci"},{"key":"3207_CR92","doi-asserted-by":"publisher","unstructured":"Rahman MM, McFadden G. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers (Basel). 2021;13(21). https:\/\/doi.org\/10.3390\/cancers13215452.","DOI":"10.3390\/cancers13215452"},{"key":"3207_CR93","doi-asserted-by":"publisher","unstructured":"Simbawa E, Al-Johani N, Al-Tuwairqi S. Modeling the Spatiotemporal Dynamics of Oncolytic Viruses and Radiotherapy as a Treatment for Cancer. Comput Math Methods Med. 2020;2020:3642654. https:\/\/doi.org\/10.1155\/2020\/3642654.","DOI":"10.1155\/2020\/3642654"},{"key":"3207_CR94","doi-asserted-by":"publisher","unstructured":"Kakiuchi Y, Kuroda S, Kanaya N, Kumon K, Tsumura T, Hashimoto M et al. Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. Mol Ther. 2021;29(10):2920-30. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.015.","DOI":"10.1016\/j.ymthe.2021.05.015"},{"key":"3207_CR95","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.canlet.2021.09.040","volume":"523","author":"W-Y Chen","year":"2021","unstructured":"Chen W-Y, Chen Y-L, Lin H-W, Chang C-F, Huang B-S, Sun W-Z, et al. Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs. Cancer Lett. 2021;523:149\u201361. https:\/\/doi.org\/10.1016\/j.canlet.2021.09.040.","journal-title":"Cancer Lett"},{"issue":"2","key":"3207_CR96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.athoracsur.2005.01.048","volume":"80","author":"PS Adusumilli","year":"2005","unstructured":"Adusumilli PS, Stiles BM, Chan M-K, Chou T-C, Wong RJ, Rusch VW, et al. Radiation Therapy Potentiates Effective Oncolytic Viral Therapy in the Treatment of Lung Cancer. Ann Thorac Surg. 2005;80(2):409\u201317. https:\/\/doi.org\/10.1016\/j.athoracsur.2005.01.048.","journal-title":"Ann Thorac Surg"},{"key":"3207_CR97","doi-asserted-by":"publisher","unstructured":"Udayakumar TS, Betancourt DM, Ahmad A, Tao W, Totiger TM, Patel M et al. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFN\u03b2, Resulting in Pronounced Antitumor Systemic Immune Responses. Molecular Cancer Research. 2020;18(8):1232-43. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-19-0836.","DOI":"10.1158\/1541-7786.Mcr-19-0836"},{"key":"3207_CR98","doi-asserted-by":"publisher","unstructured":"Pokrovska TD, Jacobus EJ, Puliyadi R, Prevo R, Frost S, Dyer A et al. External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. Cancers (Basel). 2020;12(4). https:\/\/doi.org\/10.3390\/cancers12040798.","DOI":"10.3390\/cancers12040798"},{"key":"3207_CR99","doi-asserted-by":"publisher","unstructured":"Czolk R, Schwarz N, Koch H, Sch\u00f6tterl S, Wuttke TV, Holm PS et al. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells. Int J Mol Med. 2019;44(4):1484-94. https:\/\/doi.org\/10.3892\/ijmm.2019.4296.","DOI":"10.3892\/ijmm.2019.4296"},{"key":"3207_CR100","doi-asserted-by":"publisher","unstructured":"Bieler A, Mantwill K, Holzm\u00fcller R, J\u00fcrchott K, Kaszubiak A, St\u00e4rk S et al. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. Radiother Oncol. 2008;86(3):419\u201327. https:\/\/doi.org\/10.1016\/j.radonc.2007.10.009.","DOI":"10.1016\/j.radonc.2007.10.009"},{"key":"3207_CR101","doi-asserted-by":"publisher","unstructured":"Kim SH, Wong RJ, Kooby DA, Carew JF, Adusumilli PS, Patel SG et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur J Cancer. 2005;41(2):313\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2004.10.018.","DOI":"10.1016\/j.ejca.2004.10.018"},{"key":"3207_CR102","doi-asserted-by":"publisher","unstructured":"Gao H, Zhang X, Ding Y, Qiu R, Hong Y, Chen W. Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus. Technol Cancer Res Treat. 2019;18:1533033819853290. https:\/\/doi.org\/10.1177\/1533033819853290.","DOI":"10.1177\/1533033819853290"},{"key":"3207_CR103","doi-asserted-by":"publisher","unstructured":"Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine. 2019;49:96\u2013105. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.032.","DOI":"10.1016\/j.ebiom.2019.10.032"},{"issue":"14","key":"3207_CR104","first-page":"5453","volume":"61","author":"Y Chen","year":"2001","unstructured":"Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001;61(14):5453\u201360.","journal-title":"Cancer Res"},{"key":"3207_CR105","doi-asserted-by":"publisher","unstructured":"Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L et al. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med. 2011;9:36. https:\/\/doi.org\/10.1186\/1479-5876-9-36.","DOI":"10.1186\/1479-5876-9-36"},{"key":"3207_CR106","doi-asserted-by":"publisher","unstructured":"Li H, Nakashima H, Decklever TD, Nace RA, Russell SJ. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Therapy. 2013;20(8):478\u201385. https:\/\/doi.org\/10.1038\/cgt.2013.43.","DOI":"10.1038\/cgt.2013.43"},{"issue":"4","key":"3207_CR107","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1089\/hum.2011.158","volume":"23","author":"M Opyrchal","year":"2012","unstructured":"Opyrchal M, Allen C, Iankov I, Aderca I, Schroeder M, Sarkaria J, et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther. 2012;23(4):419\u201327. https:\/\/doi.org\/10.1089\/hum.2011.158","journal-title":"Hum Gene Ther"},{"key":"3207_CR108","doi-asserted-by":"publisher","unstructured":"G\u00e1llego P\u00e9rez-Larraya J, Garcia-Moure M, Labiano S, Pati\u00f1o-Garc\u00eda A, Dobbs J, Gonzalez-Huarriz M et al. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med. 2022;386(26):2471-81. https:\/\/doi.org\/10.1056\/NEJMoa2202028.","DOI":"10.1056\/NEJMoa2202028"},{"issue":"2","key":"3207_CR109","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","volume":"89","author":"SO Freytag","year":"2014","unstructured":"Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, et al. Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer. Int J Radiation Oncology*Biology*Physics. 2014;89(2):268\u201376. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.02.034.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"3207_CR110","doi-asserted-by":"publisher","unstructured":"Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010;16(11):3067-77. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-0054.","DOI":"10.1158\/1078-0432.Ccr-10-0054"},{"key":"3207_CR111","doi-asserted-by":"publisher","unstructured":"Shirakawa Y, Tazawa H, Tanabe S, Kanaya N, Noma K, Koujima T et al. Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. Eur J Cancer. 2021;153:98\u2013108. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.043.","DOI":"10.1016\/j.ejca.2021.04.043"},{"key":"3207_CR112","doi-asserted-by":"publisher","unstructured":"Huang S, Kang Y, Liu T, Xiong Y, Yang Z, Zhang Q. The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure. Front Immunol. 2025;16:1561968. https:\/\/doi.org\/10.3389\/fimmu.2025.1561968.","DOI":"10.3389\/fimmu.2025.1561968"},{"key":"3207_CR113","doi-asserted-by":"publisher","unstructured":"Tufail M, Jiang C-H, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduction and Targeted Therapy. 2025;10(1):227. https:\/\/doi.org\/10.1038\/s41392-025-02280-1.","DOI":"10.1038\/s41392-025-02280-1"},{"key":"3207_CR114","doi-asserted-by":"publisher","unstructured":"Alam SMS, Tasnim M, Amin T, Islam SMBU. A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses. Cancer Control. 2025;32:10732748251382295. https:\/\/doi.org\/10.1177\/10732748251382295.","DOI":"10.1177\/10732748251382295"},{"key":"3207_CR115","doi-asserted-by":"publisher","unstructured":"Peterson C, Denlinger N, Yang Y. Recent Advances and Challenges in Cancer Immunotherapy. Cancers (Basel). 2022;14(16). https:\/\/doi.org\/10.3390\/cancers14163972.","DOI":"10.3390\/cancers14163972"},{"key":"3207_CR116","doi-asserted-by":"publisher","unstructured":"Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nature Communications. 2017;8(1):14754. https:\/\/doi.org\/10.1038\/ncomms14754.","DOI":"10.1038\/ncomms14754"},{"key":"3207_CR117","doi-asserted-by":"publisher","unstructured":"Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. 2018;32(1):230-3. https:\/\/doi.org\/10.1038\/leu.2017.272.","DOI":"10.1038\/leu.2017.272"},{"key":"3207_CR118","doi-asserted-by":"publisher","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109-19.e10. https:\/\/doi.org\/10.1016\/j.cell.2017.08.027.","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"3207_CR119","doi-asserted-by":"publisher","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018;36(17):1658-67. https:\/\/doi.org\/10.1200\/jco.2017.73.7379.","DOI":"10.1200\/jco.2017.73.7379"},{"key":"3207_CR120","doi-asserted-by":"publisher","unstructured":"Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I et al. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023;41(3):528\u201340. https:\/\/doi.org\/10.1200\/jco.22.00343.","DOI":"10.1200\/jco.22.00343"},{"key":"3207_CR121","doi-asserted-by":"publisher","unstructured":"Shirley CA, Chhabra G, Amiri D, Chang H, Ahmad N. Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy. Front Immunol. 2024;15:1336023. https:\/\/doi.org\/10.3389\/fimmu.2024.1336023.","DOI":"10.3389\/fimmu.2024.1336023"},{"key":"3207_CR122","doi-asserted-by":"publisher","unstructured":"Nguyen HM, Bommareddy PK, Silk AW, Saha D. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. Semin Cancer Biol. 2022;86(Pt 3):971\u201380. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.019.","DOI":"10.1016\/j.semcancer.2021.05.019"},{"key":"3207_CR123","doi-asserted-by":"publisher","unstructured":"Zhou M, Shen Z. Advanced progress in the genetic modification of the oncolytic HSV-1 virus. Front Oncol. 2024;14:1525940. https:\/\/doi.org\/10.3389\/fonc.2024.1525940.","DOI":"10.3389\/fonc.2024.1525940"},{"issue":"8","key":"3207_CR124","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/vaccines13080880","volume":"13","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Pei Y, Dong C, Liang J, Cai T, Zhang Y, et al. Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook. Vaccines. 2025;13(8):880. https:\/\/doi.org\/10.3390\/vaccines13080880.","journal-title":"Vaccines"},{"key":"3207_CR125","doi-asserted-by":"publisher","unstructured":"Hayes C. Cellular immunotherapies for cancer. Ir J Med Sci. 2021;190(1):41\u201357. https:\/\/doi.org\/10.1007\/s11845-020-02264-w.","DOI":"10.1007\/s11845-020-02264-w"},{"key":"3207_CR126","doi-asserted-by":"publisher","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y et al. Recent advances in CAR-T cell engineering. Journal of Hematology & Oncology. 2020;13(1):86. https:\/\/doi.org\/10.1186\/s13045-020-00910-5.","DOI":"10.1186\/s13045-020-00910-5"},{"key":"3207_CR127","doi-asserted-by":"publisher","unstructured":"Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31(1):134\u201353. https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.021.","DOI":"10.1016\/j.ymthe.2022.08.021"},{"key":"3207_CR128","doi-asserted-by":"publisher","unstructured":"Huang J, Zheng M, Zhang Z, Tang X, Chen Y, Peng A et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021;70(9):2453-65. https:\/\/doi.org\/10.1007\/s00262-021-02856-0.","DOI":"10.1007\/s00262-021-02856-0"},{"key":"3207_CR129","doi-asserted-by":"publisher","unstructured":"Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E et al. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther. 2021;28(1\u20132):98\u2013111. https:\/\/doi.org\/10.1038\/s41417-020-0189-4.","DOI":"10.1038\/s41417-020-0189-4"},{"key":"3207_CR130","doi-asserted-by":"publisher","unstructured":"Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. Journal of Hematology & Oncology. 2021;14(1):63. https:\/\/doi.org\/10.1186\/s13045-021-01075-5.","DOI":"10.1186\/s13045-021-01075-5"},{"key":"3207_CR131","doi-asserted-by":"publisher","unstructured":"Wing A, Fajardo CA, Posey AD Jr., Shaw C, Da T, Young RM et al. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res. 2018;6(5):605\u201316. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0314.","DOI":"10.1158\/2326-6066.Cir-17-0314"},{"key":"3207_CR132","doi-asserted-by":"publisher","unstructured":"Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC et al. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020;28(5):1251-62. https:\/\/doi.org\/10.1016\/j.ymthe.2020.02.016.","DOI":"10.1016\/j.ymthe.2020.02.016"},{"key":"3207_CR133","doi-asserted-by":"publisher","unstructured":"Ghosh R, Kumar M, Komal K, Kumar S, Sharma R, Das Gupta G. Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions. Discover Medicine. 2025;2(1):182. https:\/\/doi.org\/10.1007\/s44337-025-00328-3.","DOI":"10.1007\/s44337-025-00328-3"},{"key":"3207_CR134","doi-asserted-by":"publisher","unstructured":"Ghonime MG, Cassady KA. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018;6(12):1499\u2013510. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0014.","DOI":"10.1158\/2326-6066.Cir-18-0014"},{"key":"3207_CR135","doi-asserted-by":"publisher","unstructured":"Nguyen T-T, Ramsay L, Ahanfeshar-Adams M, Lajoie M, Schadendorf D, Alain T et al. Mutations in the IFN\u03b3-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. Clinical Cancer Research. 2021;27(12):3432-42. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3365.","DOI":"10.1158\/1078-0432.Ccr-20-3365"},{"key":"3207_CR136","doi-asserted-by":"publisher","unstructured":"Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR et al. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Mol Ther Oncolytics. 2019;13:58\u201366. https:\/\/doi.org\/10.1016\/j.omto.2019.03.008.","DOI":"10.1016\/j.omto.2019.03.008"},{"key":"3207_CR137","doi-asserted-by":"publisher","unstructured":"Matuszewska K, Santry LA, van Vloten JP, AuYeung AWK, Major PP, Lawler J et al. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer. Clin Cancer Res. 2019;25(5):1624-38. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0220.","DOI":"10.1158\/1078-0432.Ccr-18-0220"},{"key":"3207_CR138","doi-asserted-by":"publisher","unstructured":"Fu R, Qi R, Xiong H, Lei X, Jiang Y, He J et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther. 2024;9(1):118. https:\/\/doi.org\/10.1038\/s41392-024-01824-1.","DOI":"10.1038\/s41392-024-01824-1"},{"issue":"10","key":"3207_CR139","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/vaccines13101070","volume":"13","author":"M El-Tanani","year":"2025","unstructured":"El-Tanani M, Rabbani SA, Patni MA, Babiker R, Satyam SM, Rangraze IR, et al. Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis. Vaccines. 2025;13(10):1070. https:\/\/doi.org\/10.3390\/vaccines13101070.","journal-title":"Vaccines"},{"key":"3207_CR140","doi-asserted-by":"publisher","unstructured":"Chen Y, Tao M, Wu X, Tang Z, Zhu Y, Gong K et al. Current status and research progress of oncolytic virus. Pharm Sci Adv. 2024;2:100037. https:\/\/doi.org\/10.1016\/j.pscia.2024.100037.","DOI":"10.1016\/j.pscia.2024.100037"},{"key":"3207_CR141","doi-asserted-by":"publisher","unstructured":"Hao Z, Yin X, Ding R, Chen L, Hao C, Duan H. A novel oncolytic virus-based biomarker participates in prognosis and tumor immune infiltration of glioma. Frontiers in Microbiology. 2023;Volume 14\u20132023. https:\/\/doi.org\/10.3389\/fmicb.2023.1249289.","DOI":"10.3389\/fmicb.2023.1249289"},{"key":"3207_CR142","doi-asserted-by":"publisher","unstructured":"Park JS, Jang WS, Lee ME, Kim J, Oh K, Lee N et al. BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. Cancer Immunology, Immunotherapy. 2025;74(9):282. https:\/\/doi.org\/10.1007\/s00262-025-04139-4.","DOI":"10.1007\/s00262-025-04139-4"},{"key":"3207_CR143","doi-asserted-by":"publisher","unstructured":"Pakola SA, Clubb JHA, Kudling TV, van der Heijden M, Jirovec E, Arias V et al. Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. Journal for ImmunoTherapy of Cancer. 2025;13(1):e010493. https:\/\/doi.org\/10.1136\/jitc-2024-010493.","DOI":"10.1136\/jitc-2024-010493"},{"key":"3207_CR144","doi-asserted-by":"publisher","unstructured":"Matveeva OV, Chumakov PM. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev Med Virol. 2018;28(6):e2008. https:\/\/doi.org\/10.1002\/rmv.2008.","DOI":"10.1002\/rmv.2008"},{"key":"3207_CR145","doi-asserted-by":"publisher","unstructured":"Sch\u00e4fer TE, Knol LI, Haas FV, Hartley A, Pernickel SCS, J\u00e1dy A et al. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. eBioMedicine. 2024;105. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105219.","DOI":"10.1016\/j.ebiom.2024.105219"},{"key":"3207_CR146","doi-asserted-by":"publisher","unstructured":"Li J, Zhou H, Wang X, Huang K, Wang Y. Oncolytic virus VG161 offers new hope for refractory liver cancer. Front Oncol. 2025;15:1605177. https:\/\/doi.org\/10.3389\/fonc.2025.1605177.","DOI":"10.3389\/fonc.2025.1605177"},{"key":"3207_CR147","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.insi.2026.100258","volume":"2","author":"A Uthamacumaran","year":"2026","unstructured":"Uthamacumaran A, Kiyokawa J, Wakimoto H. AI-driven hybrid ecological model for predicting oncolytic viral therapy dynamics. Silico Res Biomed. 2026;2:100258. https:\/\/doi.org\/10.1016\/j.insi.2026.100258.","journal-title":"Silico Res Biomed"},{"key":"3207_CR148","doi-asserted-by":"publisher","unstructured":"Yagi C, Kuroda S, Kakiuchi Y, Hanzawa S, Kadowaki D, Yoshida Y et al. Serum extracellular vesicles containing adenoviral E1A-DNA as a predictive biomarker for liquid biopsy in oncolytic adenovirus therapy. Sci Rep. 2025;15(1):38590. https:\/\/doi.org\/10.1038\/s41598-025-22389-1.","DOI":"10.1038\/s41598-025-22389-1"},{"key":"3207_CR149","doi-asserted-by":"publisher","unstructured":"Chen L, Zuo M, Zhou Q, Wang Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Frontiers in Immunology. 2023;Volume 14\u20132023. https:\/\/doi.org\/10.3389\/fimmu.2023.1308890.","DOI":"10.3389\/fimmu.2023.1308890"},{"key":"3207_CR150","doi-asserted-by":"publisher","unstructured":"Stavrakaki E, Everts A, van den Hoogen BG, Lamfers MLM. The 16th International Oncolytic Virus Conference: Advancing oncolytic virotherapy by balancing anti-tumor and anti-viral immunity. Molecular Therapy Oncology. 2025;33(1). https:\/\/doi.org\/10.1016\/j.omton.2025.200950.","DOI":"10.1016\/j.omton.2025.200950"},{"key":"3207_CR151","doi-asserted-by":"publisher","unstructured":"Yun CO, Hong J, Yoon AR. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol. 2022;13:953410. https:\/\/doi.org\/10.3389\/fimmu.2022.953410.","DOI":"10.3389\/fimmu.2022.953410"},{"key":"3207_CR152","doi-asserted-by":"publisher","unstructured":"Peng Z, Kalim M, Lu Y. Improving systemic delivery of oncolytic virus by cellular carriers. Cancer Biology & Medicine. 2024;21(12):1104-19. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0390.","DOI":"10.20892\/j.issn.2095-3941.2024.0390"},{"key":"3207_CR153","doi-asserted-by":"publisher","unstructured":"Zhu J, Ma J, Huang M, Deng H, Shi G. Emerging delivery strategy for oncolytic virotherapy. Molecular Therapy Oncology. 2024;32(2). https:\/\/doi.org\/10.1016\/j.omton.2024.200809.","DOI":"10.1016\/j.omton.2024.200809"},{"issue":"26","key":"3207_CR154","doi-asserted-by":"publisher","first-page":"2201042","DOI":"10.1002\/adma.202201042","volume":"34","author":"Z Cong","year":"2022","unstructured":"Cong Z, Tang S, Xie L, Yang M, Li Y, Lu D, et al. Magnetic-Powered Janus Cell Robots Loaded with Oncolytic Adenovirus for Active and Targeted Virotherapy of Bladder Cancer. Adv Mater. 2022;34(26):2201042. https:\/\/doi.org\/10.1002\/adma.202201042.","journal-title":"Adv Mater"},{"key":"3207_CR155","doi-asserted-by":"publisher","unstructured":"Safarzadeh M, Saadat N, Abbasi-Molaei S, Rastegari-Pouyani M. Extracellular vesicles as missiles for enhanced anti-tumor efficacy of oncolytic viruses: from disseminating oncolysis and anti-tumor immunity to targeted delivery. Cell Communication and Signaling. 2025;23(1):276. https:\/\/doi.org\/10.1186\/s12964-025-02283-z.","DOI":"10.1186\/s12964-025-02283-z"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03207-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:50:27Z","timestamp":1785887427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03207-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":155,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3207"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03207-0","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the authors used language models in order to enhancing the writing quality and minimize unintentional plagiarism. After using language models, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article.","order":4,"name":"Ethics","label":"Using of language models","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"187"}}